This content is from: Transfer Pricing

Pfizer, Novartis and AstraZeneca among companies called to Australian senate inquiry

Nine multinational drug companies have come under scrutiny from the Australian authorities. The companies were called before a senate committee hearing today after data showed that, from their combined revenue of AUS$8.2 billion ($6.3 billion), they had paid AUS$85 million.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | 30 Day Trial